Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia

Translocation t(12;21), resulting in the ETV6-RUNX1 (or TEL-AML1) fusion protein, is present in 25% of pediatric patients with B-cell precursor acute lymphoblastic leukemia and is considered a first hit in leukemogenesis. A targeted therapy approach is not available for children with this subtype of...

Descripción completa

Detalles Bibliográficos
Autores principales: Polak, Roel, Bierings, Marc B., van der Leije, Cindy S., Sanders, Mathijs A., Roovers, Onno, Marchante, João R. M., Boer, Judith M., Cornelissen, Jan J., Pieters, Rob, den Boer, Monique L., Buitenhuis, Miranda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442983/
https://www.ncbi.nlm.nih.gov/pubmed/30381299
http://dx.doi.org/10.3324/haematol.2018.193631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442983/
https://www.ncbi.nlm.nih.gov/pubmed/30381299
http://dx.doi.org/10.3324/haematol.2018.193631

Ejemplares similares